Recruiting PHASE4 NCT00004317

Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Interventions Leucovorin calcium Pyrimethamine Spiramycin Sulfadiazine

Updated 5 times since 2017 Last updated: May 13, 2009 Started: Jul 31, 2000 Primary completion: Dec 31, 2030 Completion: Dec 31, 2030

This PHASE4 trial investigates Toxoplasmosis and is currently actively recruiting participants. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Jan 2021 — Jul 2024 [monthly]

Recruiting PHASE4
Jun 2018 — Jan 2021 [monthly]

Recruiting PHASE4
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Jul 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)
University of Chicago

Data source: Office of Rare Diseases (ORD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States